Company Analysis
Sign in

AtaiBeckley Inc. (ATAI)

ATAI · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2025
Full chart Alerts Compare
Grade5.0
◀ Past 4.2● Present 5.4▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 10 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AtaiBeckley Inc.’s names, not what it holds today.

Patents granted
33
33 utility, 1976 to Dec 31, 2025
Granted in 2025
12
Against 9 in 2024 and 9 in 2023
Applications published
61
12 of them in 2025
Names they are printed under
10
a subsidiary
By yearGrantedApplications published
'20'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals17
Organic fine chemistry14
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name10 counted
ATAI Life Sciences AG a subsidiary
named as the applicant on its applications, in DE
0 granted
25 published
Beckley Psytech Limited a subsidiary
GB, as the owner printed on each patent
11 granted
6 published
Atai Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
12 granted
1 published
Atai Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US. 2 more under the same name are not counted (printed in DE)
0 granted
12 published
Beckley Psytech Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
7 published
EmpathBio, Inc. a subsidiary
US, as the owner printed on each patent
5 granted
0 published
EmpathBio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
ATAI Life Sciences AG a subsidiary
DE, as the owner printed on each patent
2 granted
2 published
GABA Therapeutics Inc. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
GABA Therapeutics Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,492,178Stable polymorph of R-MDMA HClOrganic fine chemistryEmpathBio, Inc.
Nov 18, 202512,472,163Compositions of matter and pharmaceutical compositionsPharmaceuticalsAtai Therapeutics, Inc.
Oct 28, 202512,454,516Nitric oxide releasing prodrugs of MDA and MDMAOrganic fine chemistryEmpathBio, Inc.
Oct 7, 202512,433,896Deuterated analogs of etifoxine, their derivatives and uses thereofPharmaceuticalsGABA Therapeutics Inc.
Aug 26, 202512,396,982Compositions of matter and pharmaceutical compositionsPharmaceuticalsAtai Therapeutics, Inc.
Aug 5, 202512,378,194N, n-dimethyltryptamine salts and crystalline salt formsOrganic fine chemistryAtai Therapeutics, Inc.
Jul 8, 202512,351,537Dimethoxyphenylalkylamine activators of serotonin receptorsOrganic fine chemistryAtai Therapeutics, Inc.
Jul 1, 202512,344,570Aminotetraline activators of serotonin receptorsOrganic fine chemistryAtai Therapeutics, Inc.
Jul 1, 202512,343,319Compositions and methods for treatment of diseases and disordersPharmaceuticalsAtai Therapeutics, Inc.
Apr 15, 202512,275,735Ergoline analoguesPharmaceuticalsBeckley Psytech Limited
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388538N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMSOrganic fine chemistryAtai Therapeutics, Inc.
Sep 11, 20252025/0282712DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORSOrganic fine chemistryAtai Therapeutics, Inc.
Sep 11, 20252025/0282708AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORSOrganic fine chemistryAtai Therapeutics, Inc.
Aug 28, 20252025/0268846COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERSPharmaceuticalsAtai Therapeutics, Inc.
Aug 21, 20252025/0263372PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS THEREOFOrganic fine chemistryBeckley Psytech Limited
Jul 24, 20252025/0235428NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONSPharmaceuticalsAtai Therapeutics, Inc. · patent 12,472,163 granted from it
Jun 26, 20252025/0205191R(-)-MDMA COMPOSITIONS AND METHODS OF TREATMENTPharmaceuticalsEmpathBio, Inc.
Jun 19, 20252025/0197395IBOGAINE AND NORIBOGAINE ANALOGS AND USES THEREOFOrganic fine chemistryAtai Therapeutics, Inc.
Jun 12, 20252025/01939705-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONSPharmaceuticalsBeckley Psytech Limited
May 15, 20252025/0152553CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA AND MDA ISOMERSOrganic fine chemistryEmpathBio, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 19 · Pharmaceuticals 11 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ATAI · research, not advice